|
Patients with metastatic or locally advanced cancer are being recruited for the three investigational protocols listed below. All of these protocols are designed to test fever range whole body thermal therapy (FR-WB-TT) in combination with chemotherapy for three main reasons:
-
FR-WB-TT can increase the effect of chemotherapy drugs.
-
FR-WB-TT increases one's own immune defense against cancer cells.
-
FR-WB-TT is safe and generally well-tolerated.
This is a phase II, non-randomized study for gastric, liver, lung, and head & neck cancers, as well as melanoma and cholangioma. It combines long duration (6h), low temperature (40oC), fever-range whole body thermal therapy (FR-WB-TT) with a chemotherapy regimen of Cisplatin (CDDP), Gemcitabine (dFdC) and low-dose metronomic interferon-alpha (IFN-a). The treatment is administered on an out-patient basis.
This phase II, non-randomized study for locally advanced and metastatic pancreas cancer combines long duration (6h), low temperature (40oC), fever-range whole body thermal therapy (FR-WB-TT) with a chemotherapy regimen of Cisplatin (CDDP), Gemcitabine (dFdC) and low-dose metronomic interferon-alpha (IFN-a). The treatment is administered on an out-patient basis.Patients must undergo preliminary testing and meet strict eligibility requirements prior to being accepted into an investigational treatment protocol. An institutionally approved consent form must be signed prior to the first protocol treatment.
Created in the Division of Oncology at The University of Texas Houston Medical School
MSB 5.281, 6431 Fannin, Houston, TX 77030; Tel: 713-500-6821
Last updated on
August 3, 2009
email questions to the webmaster at oncologyweb
The content of these pages is intended for information and educational purposes. It should not be construed as medical diagnosis or treatment.